More than a decade ago, we co-developed and delivered a globally approved, first-in-class treatment for certain B-cell malignancies, including chronic lymphocytic leukemia, previously treated mantle cell lymphoma, Waldenström’s macroglobulinemia, and previously treated marginal zone lymphoma.
Today, using our full array of strategic research approaches, we are continuing to innovate to advance care and provide new treatment options for these malignancies, including non-Hodgkin lymphoma and large B-cell lymphoma. Building on our leadership and heritage in blood cancers, we are advancing the next wave of transformative medicines with novel combination regimens, antigens and costimulation.
Mantle cell lymphoma is a rare, aggressive lymphoma with an average survival rate of 5–7 years.”
B-cell malignancies by the numbers
Chronic lymphocytic leukemia
- The most common form of leukemia in the U.S.
Diffuse large B-cell lymphoma
- A fast-growing type of NHL, accounting for up to 60% of all cases worldwide
Mantle cell lymphoma
- A rare, aggressive lymphoma with an average survival rate of 5–7 years
Marginal zone lymphoma
- A slow-growing lymphoma that accounts for 8% of NHL cases
Waldenström’s macroglobulinemia
- A rare, slow-growing type of non-Hodgkin lymphoma (NHL) that occurs in less than 2% of NHL patients
